Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.49 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.46 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.46 |
| ▸ | KCNQ4 | P56696 | 2/20 | 0.46 |
| ▸ | KCNQ5 | Q9NR82 | 2/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 8/20 | 0.45 |
| ▸ | FGFR4 | P22455 | 8/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
| ▸ | TEAD1 | P28347 | 2/20 | 0.43 |
| ▸ | CCR9 | P51686 | 1/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30628654 | 1.00 | TGM2 (0.49) | TGM2KCNQ3KCNQ2KCNQ4KCNQ5 | |
| SCHEMBL26630278 | 0.89 | FGFR1 (0.50) | TGM2FGFR1FGFR4GRIN1GRIN2B | |
| SCHEMBL31336552 | 0.84 | FGFR1 (0.56) | TGM2KCNQ3KCNQ2KCNQ4KCNQ5 | |
| SCHEMBL26220303 | 0.84 | FGFR1 (0.56) | TGM2KCNQ3KCNQ2KCNQ4KCNQ5 | |
| SCHEMBL26220672 | 0.84 | TGM2 (0.49) | TGM2KCNQ3KCNQ2KCNQ4KCNQ5 | |
| SCHEMBL31336519 | 0.80 | KCNQ3 (0.50) | TGM2KCNQ3KCNQ2KCNQ4KCNQ5 | |
| SCHEMBL26220670 | 0.80 | KCNQ3 (0.50) | TGM2KCNQ3KCNQ2KCNQ4KCNQ5 | |
| SCHEMBL26220955 | 0.78 | TGM2 (0.47) | TGM2FGFR1FGFR4TEAD1NR3C1 | |
| SCHEMBL23902686 | 0.78 | KCNQ3 (0.66) | TGM2KCNQ3KCNQ2KCNQ4KCNQ5 | |
| SCHEMBL31336574 | 0.78 | FGFR1 (0.47) | TGM2KCNQ3KCNQ2KCNQ4KCNQ5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282735-A1 | BICYCLE COMPOUNDS AS TEAD INHIBITOR | DONG-A ST CO., LTD. (KR) | 2025-09-11 | — | — | US | disclosed |
| EP-4514780-A1 | BICYCLE COMPOUNDS AS TEAD INHIBITOR | Dong-A ST Co., Ltd. (KR) | 2025-03-05 | — | — | EP | disclosed |
| WO-2023209651-A1 | BICYCLE COMPOUNDS AS TEAD INHIBITOR | DONG-A ST CO., LTD. (KR) | 2023-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282735-A1 | BICYCLE COMPOUNDS AS TEAD INHIBITOR | TEAD1, TEAD2, TEAD3 | TGM2 1934/4885KCNQ3 2662/4885KCNQ2 1705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.